AN2 Therapeutics Inc

AN2 Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics. Its lead candidate, epetraborole, is in a phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease and is also being studied for the treatment of acute melioidosis. The company is developing AN2-502998 (AN15368), an investigational boron-based small molecule in preclinical trials for chronic Chagas disease, and has research programs targeting novel compounds in oncology and infectious disease based on its boron chemistry platform. AN2 Therapeutics has license agreements with Anacor Pharmaceuticals, Inc., Brii Biosciences Limited for epetraborole in China, Hong Kong, Taiwan, and Macau, and GSK plc for the development of new therapies for TB. The company was incorporated in 2017 and is headquartered in Menlo Park, California.

Biotech & Genomic Medicine▲

AN2 Therapeutics Presents Epetraborole Data at SOHO 2026

AN2 Therapeutics, Inc. (Nasdaq: ANTX) announced that four abstracts supporting the development of epetraborole, a novel boron-containing oral candidate for polycythemia vera, will be presented at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting, held September 9-12 in Houston. The abstracts highlight potential beneficial effects on erythropoiesis and hemoglobin-related parameters across clinical and nonclinical studies, with exposure-response relationships in nonhuman primates predicting human effects. George H. Talbot, M.D., Co-Founder and Senior Medical Advisor, noted the data strengthen understanding of exposure-response relationships supporting development. The company is a clinical-stage biopharmaceutical firm focused on boron chemistry-based small molecules.

ANTX ▲

Biotech & Genomic Medicine

Business Wire·18dRead more →